Vertex EU Positive Opinion for Expanded Label for Cystic Fibrosis Combo

 -If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time-

https://www.businesswire.com/news/home/20250227357008/en/Vertex-Receives-CHMP-Positive-Opinion-for-Expanded-Label-for-KAFTRIO%C2%AE-in-Combination-With-Ivacaftor-for-People-With-Cystic-Fibrosis-to-Include-Rare-Mutations